{"id":"r-minichop-acalabrutinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Bleeding/bruising"}]},"_chembl":{"chemblId":"CHEMBL4747506","moleculeType":"Unknown","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R-miniCHOP is a reduced-intensity chemotherapy regimen (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) that kills lymphoma cells and activates immune responses. Acalabrutinib selectively inhibits Bruton tyrosine kinase (BTK), a key signaling molecule in B-cell lymphomas and immune cells, thereby reducing tumor cell survival and enhancing anti-tumor T-cell responses. The combination aims to improve efficacy in lymphoma treatment while potentially reducing chemotherapy toxicity.","oneSentence":"R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:03.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma (phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT05820841","phase":"PHASE3","title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-06-07","conditions":"Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-miniCHOP + Acalabrutinib","genericName":"R-miniCHOP + Acalabrutinib","companyName":"Universität des Saarlandes","companyId":"universit-t-des-saarlandes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity. Used for B-cell non-Hodgkin lymphoma (phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}